Retinoic acid receptor beta 2 (RARβ2) (RARβ2)

Retinoic acid receptor beta (RARβ), specifically the RARβ2 isoform, is a member of the nuclear receptor superfamily that functions as a ligand-dependent transcription factor [1]. It plays a critical role in mediating the biological effects of retinoic acid, a derivative of Vitamin A, which regulates essential processes such as cell growth, differentiation, and apoptosis [1, 2]. RARβ2 is widely recognized as a potent tumor suppressor; its expression is frequently lost or silenced in various human cancers, including lung, breast, and head and neck carcinomas, often through epigenetic mechanisms like promoter hypermethylation [2, 3]. In the context of drug development, RARβ2 is a target for synthetic retinoids and re-expression therapies. Retinoid drugs bind to the receptor to trigger transcriptional programs that inhibit tumor cell proliferation, while epigenetic modulators like DNA methyltransferase inhibitors are used to restore RARβ2 mRNA expression in silenced cells [3, 4]. Beyond oncology, RARβ2 has been investigated for its role in promoting axonal regeneration in the central nervous system, making it a target of interest for spinal cord injury and neurodegenerative diseases [5].

Other names

RARBNR1B2Retinoic acid receptor beta 2RAR-epsilonHAPRRB2

Ligand-activated transcription factor that binds to retinoic acid response elements (RAREs) to regulate gene expression [1, 4]. In cancer, DNA methyltransferase inhibitors are used to restore silenced RARβ2 mRNA expression [3].